Posted on:Weil in the News
Weil represented CBC Group as the lead investor on the consortium aspects in connection with its acquisition of approximately 43% equity in Yaneng Bioscience (Shenzhen) Co., Ltd. (Yaneng) for an aggregate consideration of approximately $390 million. The underlying transaction documents with Yaneng and existing shareholders were signed on September 30, 2021.
CBC Group (formerly C-Bridge Capital) is one of the largest and most active healthcare-dedicated investment ﬁrms in Asia.
Headquartered in Shenzhen, China, Yaneng is a leading biotechnology company specializing in the research and development, production, sales and technical services of in vitro diagnostic reagents and testing instruments.